Improvements in Frailty Care as Cost Effective

By Staff Writer

January 15, 2024

Frailty care improvements

Frail patients require a robust system during hospital admission to decrease deconditioning risk and hasten discharge. In recent years, a significant effort has gone into quickly identifying these patients. Specialists evaluate them as part of a Frailty Liaison Team. This study examines the effect of these metrics on patient outcomes, as published in the Future Healthcare Journal. 

The Importance of Locating and Transferring Patients at an Early Stage

According to the findings of previous research, proposed internal transfers frequently face delays or may not take place at all. In 2017, hospitals moved three-fifths of fragile patients to appropriate wards. These delays likely influence the duration of hospital stays. This assumption is based on the specialised care frailty units provide. 

A Discussion of the Research Methodology

The Frailty Liaison Team performs the Comprehensive Geriatric Assessment (CGA) on patients classified as frail. These patients receive treatment on the Clinical Decisions Unit (CDU) or the Acute Medical Unit (AMU). This study compares the length of stay for patients transferred to a frailty ward on the assessment day with those transferred after 24 hours. 

The findings of the research study

According to the findings of the study, early transfers result in a hospital stay that is reduced by more than one day. This results in a reduction in direct costs as well as a reduction in the patient’s exposure toward harm that is associated with the hospital. According to this study frailty care improvements could lead to potential annual saving of £26,640.

The Consequences That the Study Could Have

Because of the favourable findings of the study, conversations have begun regarding the possibility of improving the local frailty route. The authors will use the data to identify potential improvements in patient care and compare different discharge procedures. 

The findings of this study emphasise the need of identifying frail individuals at an early stage and transferring them to specialised wards to receive treatment. They have the potential to greatly enhance patient outcomes while also lowering the expense of healthcare. 

 

Reference url

Recent Posts

oral GLP-1 medication
    

Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

🌟 Ready for a breakthrough in diabetes management?

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a successful Phase 3 trial, showing remarkable efficacy in lowering A1C levels and promoting substantial weight loss. As the first oral small molecule GLP-1 receptor agonist, it offers a promising alternative to conventional injectable treatments, potentially improving patient adherence and access.

Dive into the details of this exciting development and what it means for the future of diabetes care!

#SyenzaNews #HealthTech #Innovation #Pharmaceuticals

pediatric thyroid cancer risk
    

Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from a California Study

🌟 Are we overlooking environmental risks in pediatric cancer?

Recent research highlights a troubling link between perinatal exposure to PM2.5 and outdoor artificial light and the increased risk of pediatric thyroid cancer. This pivotal study sheds light on how environmental factors play a critical role in childhood health, particularly among vulnerable populations.

Dive into this important discussion on how addressing these environmental exposures may reduce pediatric thyroid cancer and improve health outcomes for future generations.

#SyenzaNews #EnvironmentalHealth #HealthPolicy #Innovation

capivasertib cost-effectiveness
      

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.